COVID-19 studies for: C19 studies:  HC QHC Q IvermectinIVM Vitamin DVitamin D ZincZn REGN-COV2REGN LY-CoVLY RemdesivirRMD
HC Q study #122
Source   PDF   Share   Tweet
See all 182 studies
9/9
Negative
Pre-Exposure Prophylaxis study (treated before exposed to the virus)
Rentsch et al., The Lancet Rheumatology, doi:10.1016/S2665-9913(20)30378-7 (preprint 9/9, https://www.medrxiv.org/content/10.1101/2020.09.04.20187781v1) (Peer Reviewed)
Effect of pre-exposure use of hydroxych loroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform
Observational database study of RA/SLE patients in the UK, 194,637 RA/SLE patients with 30,569 having >= 2 HC Q prescriptions in the prior 6 months, HC Q HR 1.03 [0.80-1.33] (HR 0.78 before adjustments).
70 patients with HC Q prescriptions died. One major problem is that there is no knowlege of medication adherence for these 70 - for example, it is possible that they were part of the expected percentage of patients that did not take the medication as prescribed, invalidating the result.
Both confirmed and suspected deaths were included. It is not clear why the authors did not report the result for only confirmed cases. It has been reported that several thousand deaths were incorrectly declared as COVID-19 in the UK.
Other limitations: confounding by use of bDMARDs, confounding by severity of rheumatological disease.
death, ↑3.0%, p=0.83
Source   PDF   Share   Tweet
See all 182 studies
Please send us corrections, updates, or comments.
Submit